Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...

Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...

Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...

Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...

Oppenheimer has initiated coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) off at outperform highlighting the biotech's SADA platform, calling it "the most advanced pre-targeting platform currently ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Y-mAbs Therapeutics Inc (NASDAQ:YMAB) is set to release its Q3 2024 earnings on Nov 8, 2024. The consensus estimate for Q3 2024 revenue is $23.26 million, and the earnings are expected to come in ...

GET MORE AI-GENERATED SIGNALS: November 26, 2024, 20:22 pm ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...